Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IACH MATH 2020 | MRD in AML: ELN recommendations

Arnon Nagler • 7 Jun 2020
IACH MATH 2020
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia

Arnon Nagler, MD, Sheba Medical Center, Tel-Aviv, Israel, gives an overview of the European LeukemiaNet (ELN) recommendations on measurable residual disease (MRD) in acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Arnon Nagler

Transplanting patients with advanced AML 3:07
Transplanting patients with advanced AML
Arnon Nagler • 30 Mar 2025
Bone marrow versus mobilized peripheral blood grafts for haploidentical transplant in secondary AML 1:42
Bone marrow versus mobilized peripheral blood grafts for haploidentical transplant in secondary AML
Arnon Nagler • 30 Mar 2025
Is there a preferable donor for alloSCT in secondary AML in first complete remission? 2:23
Is there a preferable donor for alloSCT in secondary AML in first complete remission?
Arnon Nagler • 30 Mar 2025
Advancements in a point-of-care approach to CAR T-cell manufacturing & ongoing programs 3:22
Advancements in a point-of-care approach to CAR T-cell manufacturing & ongoing programs
Arnon Nagler • 30 Mar 2025

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals